A Phase III Adjuvant Trial Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression plus Endocrine Therapy in Premenopausal Patients with pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score ≤ 25 (OFSET)
| Protocol No. | CTO-NRG-BR009 | Scope | National |
|---|---|---|---|
| Principal Investigator | Tarah Ballinger | Treatment Type | Treatment |
| Age Group | Adult | Phase | Phase III |
